Chronic subhepatotoxic exposure to arsenic enhances hepatic injury caused by high fat diet in mice

Toxicology and Applied Pharmacology

Volumn 257, Issue 3, 2011, Pages 356-364

  Tan, Min ^a   Schmidt, Robin H ^a   Beier, Juliane I ^a   Watson, Walter H ^a,b   Zhong, Hai ^a,b   States, J Christopher ^a   Arteel, Gavin E ^a,b  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

Author keywords

Metabolic syndrome; Non alcoholic fatty liver disease; Obesity; Sodium arsenite

Indexed keywords

ALANINE AMINOTRANSFERASE; ARSENIC; ARSENITE SODIUM; ASPARTATE AMINOTRANSFERASE; FIBRIN; TAP WATER; ARSENOUS ACID DERIVATIVE; SODIUM DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; C57BL 6 MOUSE; CHEMICAL ANALYSIS; CONTROLLED STUDY; EXTRACELLULAR MATRIX; HISTOPATHOLOGY; LIPID DIET; LIVER INJURY; LIVER TOXICITY; LONG TERM EXPOSURE; LOW FAT DIET; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; WEIGHT GAIN; ANIMAL; C57BL MOUSE; DISEASE MODEL; FAT INTAKE; FATTY LIVER; INFLAMMATION; LIVER FUNCTION TEST; METABOLISM; PATHOPHYSIOLOGY; RISK FACTOR; TOXIC HEPATITIS;

ANIMALIA; MUS;

ANIMALS; ARSENITES; DIETARY FATS; DISEASE MODELS, ANIMAL; DRUG-INDUCED LIVER INJURY; EXTRACELLULAR MATRIX; FATTY LIVER; FIBRIN; INFLAMMATION; LIVER FUNCTION TESTS; MALE; MICE; MICE, INBRED C57BL; RISK FACTORS; SODIUM COMPOUNDS; WEIGHT GAIN;

EID: 84855900030     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2011.09.019     Document Type: Article

References (46)

1. Adams L.A., Lymp J.F., St Sauver J., Sanderson S.O., Lindor K.D., Feldstein A., Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 129:113-121.
2. Arteel G.E., Guo L., Schlierf T., Beier J.I., Kaiser J.P., Chen T.S., Liu M., Conklin D.J., Miller H.L., von Montfort C., States J.C. Subhepatotoxic exposure to arsenic enhances lipopolysaccharide-induced liver injury in mice. Toxicol. Appl. Pharmacol. 2008, 226:128-139.
3. Beier J.I., Guo L., von Montfort C., Kaiser J.P., Joshi-Barve S., Arteel G.E. New role of resistin in lipopolysaccharide-induced liver damage in mice. J. Pharmacol. Exp. Ther. 2008, 325:801-808.
4. Beier J.I., Luyendyk J.P., Guo L., von Montfort C., Staunton D.E., Arteel G.E. Fibrin accumulation plays a critical role in the sensitization to lipopolysaccharide-induced liver injury caused by ethanol in mice. Hepatology 2009, 49:1545-1553.
5. Bergheim I., Luyendyk J.P., Steele C., Russell G.K., Guo L., Roth R.A., Arteel G.E. Metformin prevents endotoxin-induced liver injury after partial hepatectomy. J. Pharmacol. Exp. Ther. 2005, 316:1053-1061.
6. Bergheim I., Guo L., Davis M.A., Lambert J.C., Beier J.I., Duveau I., Luyendyk J.P., Roth R.A., Arteel G.E. Metformin prevents alcohol-induced liver injury in the mouse: critical role of plasminogen activator inhibitor-1. Gastroenterology 2006, 130:2099-2112.
7. Centers for Disease Control and Prevention Behavioral Risk Factor Surveillance System: Turning Information into Action 2-5-2007. http://www.cdc.gov/brfss/.
8. Chen H., Li S., Liu J., Diwan B.A., Barrett J.C., Waalkes M.P. Chronic inorganic arsenic exposure induces hepatic global and individual gene hypomethylation: implications for arsenic hepatocarcinogenesis. Carcinogenesis 2004, 25:1779-1786.
9. Choi S., Diehl A.M. Role of inflammation in nonalcoholic steatohepatitis. Curr. Opin. Gastroenterol. 2005, 21:702-707.
10. Clark J.M. The epidemiology of nonalcoholic fatty liver disease in adults. J. Clin. Gastroenterol. 2006, 40:S5-S10.
11. Day C.P. Non-alcoholic fatty liver disease: current concepts and management strategies. Clin. Med. 2006, 6:19-25.
12. Day C.P., James O.F. Steatohepatitis: a tale of two "hits"?. Gastroenterology 1998, 114:842-845.
13. Diehl A.M., Li Z.P., Lin H.Z., Yang S.Q. Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut 2005, 54:303-306.
14. Engel R.R., Smith A.H. Arsenic in drinking water and mortality from vascular disease: an ecologic analysis in 30 counties in the United States. Arch. Environ. Health. 1994, 49:418-427.
15. Flegal K.M., Carroll M.D., Kuczmarski R.J., Johnson C.L. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int. J. Obes. Relat Metab Disord. 1998, 22:39-47.
16. Frost F.J., Muller T., Petersen H.V., Thomson B., Tollestrup K. Identifying US populations for the study of health effects related to drinking water arsenic. J. Expo. Anal. Environ. Epidemiol. 2003, 13:231-239.
17. Ganey P.E., Luyendyk J.P., Maddox J.F., Roth R.A. Adverse hepatic drug reactions: inflammatory episodes as consequence and contributor. Chem. Biol. Interact. 2004, 150:35-51.
18. Hall M., Chen Y., Ahsan H., Slavkovich V., van Geen A., Parvez F., Graziano J. Blood arsenic as a biomarker of arsenic exposure: results from a prospective study. Toxicology 2006, 225:225-233.
19. Hewett J.A., Roth R.A. The coagulation system, but not circulating fibrinogen, contributes to liver injury in rats exposed to lipopolysaccharide from gram-negative bacteria. J. Pharmacol. Exp. Ther. 1995, 272:53-62.
20. Holdsworth S.R., Thomson N.M., Glasgow E.F., Atkins R.C. The effect of defibrination on macrophage participation in rabbit nephrotoxic nephritis: studies using glomerular culture and electron microscopy. Clin. Exp. Immunol. 1979, 37:38-43.
21. Kaiser J.P., Beier J.I., Zhang J., David H.J., von Montfort C., Guo L., Zheng Y., Monia B.P., Bhatnagar A., Arteel G.E. PKCepsilon plays a causal role in acute ethanol-induced steatosis. Arch. Biochem. Biophys. 2009, 482:104-111.
22. Kozul C.D., Nomikos A.P., Hampton T.H., Warnke L.A., Gosse J.A., Davey J.C., Thorpe J.E., Jackson B.P., Ihnat M.A., Hamilton J.W. Laboratory diet profoundly alters gene expression and confounds genomic analysis in mouse liver and lung. Chem. Biol. Interact. 2008, 173:129-140.
23. Kruithof E.K. Plasminogen activator inhibitors-a review. Enzyme 1988, 40:113-121.
24. Loike J.D., el Khoury J., Cao L., Richards C.P., Rascoff H., Mandeville J.T., Maxfield F.R., Silverstein S.C. Fibrin regulates neutrophil migration in response to interleukin 8, leukotriene B4, tumor necrosis factor, and formyl-methionyl-leucyl-phenylalanine. J. Exp. Med. 1995, 181:1763-1772.
25. Ludwig J., Viggiano T.R., McGill D.B., Oh B.J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 1980, 55:434-438.
26. Mazumder D.N. Effect of chronic intake of arsenic-contaminated water on liver. Toxicol. Appl. Pharmacol. 2005, 206:169-175.
27. Mokdad A.H., Ford E.S., Bowman B.A., Dietz W.H., Vinicor F., Bales V.S., Marks J.S. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003, 289:76-79.
28. National Center for Health Statistics (NCHS) Health, United States, 2001, with Urban and Rural Health Chart Book 2001, National Center for Health Statistics, Hyattsville, MD.
29. National Research Council Arsenic in drinking water 1999, National Academy Press, Washington, DC.
30. National Research Council Arsenic in drinking water: 2001 update 2001, National Academy Press, Washington, DC.
31. Navas-Acien A., Silbergeld E.K., Pastor-Barriuso R., Guallar E. Rejoinder: Arsenic exposure and prevalence of type 2 diabetes: updated findings from the National Health Nutrition and Examination Survey, 2003-2006. Epidemiology 2009, 20:816-820.
32. Ogden C.L., Carroll M.D., Curtin L.R., McDowell M.A., Tabak C.J., Flegal K.M. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006, 295:1549-1555.
33. Paul D.S., Walton F.S., Saunders R.J., Styblo M. Characterization of the impaired glucose homeostasis produced in C57BL/6 mice by chronic exposure to arsenic and high-fat diet. Environ. Heal. Perspect. 2011, 119:1104-1109.
34. Pearson J.M., Schultze A.E., Schwartz K.A., Scott M.A., Davis J.M., Roth R.A. The thrombin inhibitor, hirudin, attenuates lipopolysaccharide-induced liver injury in the rat. J. Pharmacol. Exp. Ther. 1996, 278:378-383.
35. Santra A., Das G.J., De B.K., Roy B., Guha Mazumder D.N. Hepatic manifestations in chronic arsenic toxicity. Indian J. Gastroenterol. 1999, 18:152-155.
36. Santra A., Maiti A., Das S., Lahiri S., Charkaborty S.K., Mazumder D.N. Hepatic damage caused by chronic arsenic toxicity in experimental animals. J. Toxicol. Clin. Toxicol. 2000, 38:395-405.
37. Smith A.H., Hopenhayn-Rich C., Bates M.N., Goeden H.M., Hertz-Picciotto I., Duggan H.M., Wood R., Kosnett M.J., Smith M.T. Cancer risks from arsenic in drinking water. Environ. Heal. Perspect. 1992, 97(259-67):259-267.
38. Straub A.C., Stolz D.B., Ross M.A., Hernandez-Zavala A., Soucy N.V., Klei L.R., Barchowsky A. Arsenic stimulates sinusoidal endothelial cell capillarization and vessel remodeling in mouse liver. Hepatology 2007, 45:205-212.
39. Tilg H. The role of cytokines in non-alcoholic fatty liver disease. Dig. Dis. 2010, 28:179-185.
40. United States Geological Survey Arsenic in Ground Water of the United States 2-7-2007. http://water.usgs.gov/nawqa/trace/arsenic/.
41. Waalkes M.P., Liu J., Chen H., Xie Y., Achanzar W.E., Zhou Y.S., Cheng M.L., Diwan B.A. Estrogen signaling in livers of male mice with hepatocellular carcinoma induced by exposure to arsenic in utero. J. Natl. Cancer Inst. 2004, 96:466-474.
42. Waalkes M.P., Liu J., Ward J.M., Diwan B.A. Enhanced urinary bladder and liver carcinogenesis in male CD1 mice exposed to transplacental inorganic arsenic and postnatal diethylstilbestrol or tamoxifen. Toxicol. Appl. Pharmacol. 2006, 215:295-305.
43. Wanless I.R., Wong F., Blendis L.M., Greig P., Heathcote E.J., Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology 1995, 21:1238-1247.
44. Welch A.H., Watkins S.A., Helsel D.R., Focazio M.J. Arsenic in ground-water resources of the United States. U.S. Geological Survey Fact Sheet FS-063-00 2000.
45. Wouters K., van Gorp P.J., Bieghs V., Gijbels M.J., Duimel H., Lutjohann D., Kerksiek A., van Kruchten R., Maeda N., Staels B., van Bilsen M., Shiri-Sverdlov R., Hofker M.H. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology 2008, 48:474-486.
46. Yang S.Q., Lin H.Z., Lane M.D., Clemens M., Diehl A.M. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:2557-2562.